Zantac Users May Want to be Checked For Gastro-Intestinal Cancers

Cancer could have developed decades ago without showing any symptoms

Friday, May 1, 2020 - Users of Zantac are surprised to find that their retailer of choice, Walmart, CVS, or Rite Aid no longer carries their favorite brand of antacid medication. Zantac, previously the world's most popular and best-selling over the counter heartburn and acid reflux medication, has been taken off the market by its manufacturer and recalled by the US Food and Drug Administration because researchers have found excessively high levels of NDMA, a known carcinogenic substance in the product. The National Institute of Health conducted a meta-analysis of nitrate and NDMA data and concluded: "dietary nitrates intake was associated with a reduced risk of gastric cancer, and high consumption of nitrites and NDMA could increase the risk."

Zantac users are suspected of developing a variety of life-threatening cancer from regularly taking the drug. Zantac users should preemptively see their doctors because cancer of this type can have a latency period of decades and diagnosing cancer in its earliest stage is the key to successfully treating the disease. If you have been a regular Zantac user at any time over the previous 20 years you may wish to be checked for cancer of the stomach, bladder, esophagus, prostate, and gastrointestinal tract. If the tests are negative, so much the better, but if you do have cancer, you may wish to contact a Zantac stomach cancer lawyer for a free consultation as to how to file a claim against the drug's manufacturer Sanofi for a lump sum monetary award.

The most recent complaint of this nature against Sanofi has been filed by Douglas Rochler and his wife, Anna Maria in the U.S. District Court for the Eastern District of Texas. According to About Lawsuits.com, the complaint "(indicates) the manufacturers of the widely used heartburn drug knew or had reason to know Zantac exposes users to unsafe levels of the cancer-causing chemical, yet placed profits before consumer safety and continued to aggressively market the unreasonably dangerous drug." These are serious accusations and bellwether trials are about to get underway that could award hundreds of millions of dollars to plaintiffs that were told by the company for decades that Zantac was safe. There is reason to believe that Sanofi executives looked the other way and had a responsibility to test the product during its shelf life for increases in the cancer-causing substance. Also, researchers are now saying that Zantac interacts with nitrates (preservatives) in foods that could elevate the levels of NDMA to carcinogenic levels.

According to About Lawsuits, Mr. Rochler took Zantac about four or five times per week for around five years and developed severe cancer that required several surgeries and the removal of much of his gastrointestinal system. "As a result of the exposure to NDMA, Rochler indicates that he was diagnosed with bladder cancer and had to undergo multiple surgeries between June and November 2017, including transurethral resection of a bladder tumor, as well as a radical cystectomy with a neobladder."

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.